TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35181532

Group type: EXPERIMENTAL
Intervention: Active tDCS (1.5 mA for 20 minutes over two consecutive weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 41
Study: 32950829

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30–50 mg·kg−1 intravenously as a bolus before induction, followed by 10–20 mg·kg−1 h−1 continuous infusion during surgery)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study: 36199107

Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Waiting List Control (WL)
Number of subjects: 200
Study: 33750533

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting group
Number of subjects: 0
Study: 32564251

Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 35002241

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no fluoxetine)
Number of subjects: 50
Study: 616351330

Group type: EXPERIMENTAL
Intervention: Liquid L‐T4 formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tablet form L‐T4
Number of subjects: 0
Study: 35089948

Group type: EXPERIMENTAL
Intervention: Version 1 of the EEfRT
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Version 2 of the EEfRT
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Original EEfRT
Number of subjects: 514
Study: 33556204

Group type: EXPERIMENTAL
Intervention: oXiris
Number of subjects: 20

Group type: COMPARATOR
Intervention: M150
Number of subjects: 20
Study: 36197179

Group type: EXPERIMENTAL
Intervention: Preoperative walking enhanced by goal setting with an activity monitor and telephonic coaching
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study: 33607177

Group type: EXPERIMENTAL
Intervention: Baricitinib (Jak1/2 inhibitor), oral treatment for four weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 100
Study: 32359843

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 537

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 537
Study: 35393472

Group type: EXPERIMENTAL
Intervention: Damped maskers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramped maskers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disconnected sentences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stories with randomized sentence order
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engaging and coherent narrative stories
Number of subjects: 0
Study: 34083663

Group type: EXPERIMENTAL
Intervention: Heat‐not‐Burn cigarette (HNBC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tobacco cigarette (Tcig)
Number of subjects: 75
Study: 34967496

Group type: EXPERIMENTAL
Intervention: CVVHDF
Number of subjects: 60

Group type: COMPARATOR
Intervention: CVVH
Number of subjects: 60
Study: 33236949

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 32
Study: 35429309

Group type: EXPERIMENTAL
Intervention: PrEP initiation among clients visiting specifically to initiate PrEP
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: PrEP initiation among clients visiting for HIV testing
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: PrEP initiation among clients visiting for outpatient services
Number of subjects: 1782

Group type: EXPERIMENTAL
Intervention: Preferred delivery settings among those who initiated PrEP
Number of subjects: 1782
Study: 32159857

Group type: EXPERIMENTAL
Intervention: Micro-CT method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiographic method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Randomization method
Number of subjects: 60
Study: 35060403

Group type: EXPERIMENTAL
Intervention: CSD500
Number of subjects: 500
Study: 34080008

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1058
Study: 36303868

Group type: EXPERIMENTAL
Intervention: 1.5 g of white common bean extract (WCBE) taken half an hour before a meal (Group W)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1.5 g of maltodextrin as a placebo (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.5 g of white common bean extract (WCBE) (Group W)
Number of subjects: 90
Study: 35607722

Group type: EXPERIMENTAL
Intervention: Provider's personal phone number (PPN) group
Number of subjects: 507

Group type: COMPARATOR
Intervention: Control group (no PPN)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Provider's PPN
Number of subjects: 507
Study: 33118055

Group type: EXPERIMENTAL
Intervention: High nicotine concentration (15.8 mg/g)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Moderate nicotine concentration (5.2 mg/g)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Low nicotine concentration (0.4 mg/g)
Number of subjects: 360
Study: 35068061

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily + tamsulosin 0.4 mg once daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo + tamsulosin 0.4 mg once daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) + tamsulosin
Number of subjects: 63
Study: 34691317

Group type: EXPERIMENTAL
Intervention: Moxibustion plus routine drug therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine drug therapy (Control)
Number of subjects: 68
Study: 98241980

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-treatment liver histology
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Biochemical remission
Number of subjects: 25
Study: 34924405

Group type: EXPERIMENTAL
Intervention: 10Hz rTMS at the ipsilesional M1 and 1Hz rTMS at the contralesional M1
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bilateral sham stimulation at the motor cortices
Number of subjects: 44
Study: 36498228

Group type: EXPERIMENTAL
Intervention: 770 mg/day of Tribulus terrestris L. (TT) for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo daily for 6 weeks
Number of subjects: 30
Study: 34469394

Group type: EXPERIMENTAL
Intervention: AutonoMe injector with Clareon IOL
Number of subjects: 30

Group type: COMPARATOR
Intervention: iSert injector with Vivinex IOL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both injectors
Number of subjects: 30
Study: 35442404

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 35397657

Group type: EXPERIMENTAL
Intervention: Antegrade fixation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Retrograde fixation
Number of subjects: 30
Study: 34176002

Group type: EXPERIMENTAL
Intervention: Preventive interventions (specific interventions not detailed)
Number of subjects: 851
Study: 32128909

Group type: EXPERIMENTAL
Intervention: Survivorship planning consultation (SPC)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control arm (time-controlled wellness rehabilitation consultation)
Number of subjects: 198
Study: 36241249

Group type: EXPERIMENTAL
Intervention: Adjunctive plasma exchange therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Intensive immunosuppressive therapy
Number of subjects: 95
Study: 35631229

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (100 mg oral daily for 1 month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34362654

Group type: EXPERIMENTAL
Intervention: Minimally invasive technique
Number of subjects: 18

Group type: COMPARATOR
Intervention: Open surgical technique
Number of subjects: 18
Study: 35137108

Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous vagus nerve stimulation (atVNS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45
Study: 34061402

Group type: EXPERIMENTAL
Intervention: Ceramic implants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Titanium implants
Number of subjects: 30
Study: 34371847

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum HAC01 (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study: 32460465

Group type: EXPERIMENTAL
Intervention: Normocarbia (PaCO2: 38‒42 mmHg) for 30 min
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hypercarbia (PaCO2: 45‒50 mmHg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of normocarbia and hypercarbia
Number of subjects: 50
Study: 36301752

Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33979200

Group type: EXPERIMENTAL
Intervention: VA BIC
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 19
Study: 32760093

Group type: EXPERIMENTAL
Intervention: Topical lidocaine jelly and sub‐Tenon anesthesia with 2 4 ml of 1% ropivacaine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Peribulbar anesthesia with 4 6 ml of 1% ropivacaine
Number of subjects: 54
Study: 34761595

Group type: EXPERIMENTAL
Intervention: 125I radioactive seed implantation combined with EGFR-TKIs
Number of subjects: 108

Group type: COMPARATOR
Intervention: EGFR-TKIs alone
Number of subjects: 108
Study: 35843923

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg tablet (test product)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Olanzapine 10 mg tablet (reference product)
Number of subjects: 24
Study: 33465818

Group type: EXPERIMENTAL
Intervention: Regular daily intake of PPIs
Number of subjects: 1298
Study: 36153652

Group type: EXPERIMENTAL
Intervention: Third Marriage Checkup (MC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no third MC)
Number of subjects: 63
Study: 32898318

Group type: EXPERIMENTAL
Intervention: Single stenting
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Dual stenting
Number of subjects: 1002
Study: 32939553

Group type: EXPERIMENTAL
Intervention: Vitamin A Supplementation (VAS) 50,000 IU
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 306
Study: 34880668

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate sub‐diaphragmatic irrigation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal saline sub‐diaphragmatic irrigation
Number of subjects: 70
Study: 33049114

Group type: EXPERIMENTAL
Intervention: Verubecestat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lanabecestat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verubecestat and Lanabecestat
Number of subjects: 0
Study: 32444867

Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide and dexamethasone (Isa-Pd)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone (Pd)
Number of subjects: 104
Study: 32118759

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 100
Study: 36182782

Group type: EXPERIMENTAL
Intervention: retractor-endoscopic carpal tunnel syndrome (rCTS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: open carpal tunnel syndrome (oCTS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: retractor-endoscopic cubital tunnel syndrome (rCbTS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: open cubital tunnel syndrome (oCbTS)
Number of subjects: 80
Study: 34229078

Group type: EXPERIMENTAL
Intervention: Recombinant human albumin (rHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human serum albumin (HSA)
Number of subjects: 0
Study: 32719253

Group type: EXPERIMENTAL
Intervention: Probiotics group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Candid group
Number of subjects: 86
Study: 33203613

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Anti-histamine
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Opioid pathway related treatment
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 1180
Study: 32011717

Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation (MiECC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation
Number of subjects: 60
Study: 34448742

Group type: EXPERIMENTAL
Intervention: CXR-positive pneumonia cases
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: S. pneumoniae
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: H. influenza
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Hospitalized cases
Number of subjects: 630
Study: 32106812

Group type: EXPERIMENTAL
Intervention: PECS + ESP
Number of subjects: 30

Group type: COMPARATOR
Intervention: ESP
Number of subjects: 30
Study: 35597794

Group type: EXPERIMENTAL
Intervention: Phaco-canaloplasty (PC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Phaco-non-penetrating deep sclerectomy (PDS)
Number of subjects: 75
Study: 34764311

Group type: EXPERIMENTAL
Intervention: Structured exercise (3-day program with initial education and three daily active exercise sessions)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no structured exercise)
Number of subjects: 61
Study: 32352714

Group type: EXPERIMENTAL
Intervention: Open-label rifaximin 550 mg 3 times daily for 2 weeks
Number of subjects: 2438

Group type: EXPERIMENTAL
Intervention: Double-blind rifaximin 550 mg 3 times daily
Number of subjects: 2438
Study: 33787561

Group type: EXPERIMENTAL
Intervention: PFMT using the motion-based digital therapeutic device
Number of subjects: 61

Group type: COMPARATOR
Intervention: PFMT alone (control group)
Number of subjects: 61
Study: 33979219

Group type: EXPERIMENTAL
Intervention: Low-frequency contact ultrasonic debridement therapy (LFCUD) with polyhexamethylene biguanide (PHMB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-frequency contact ultrasonic debridement therapy (LFCUD) alone
Number of subjects: 50
Study: 36368336

Group type: EXPERIMENTAL
Intervention: 9-month oral regimen with bedaquiline
Number of subjects: 588

Group type: COMPARATOR
Intervention: 9-month control regimen
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: 6-month regimen with bedaquiline and 8 weeks of second-line injectable
Number of subjects: 588
Study: 35247743

Group type: EXPERIMENTAL
Intervention: Intra-pleural immunotherapy (part of the TILT trial)
Number of subjects: 12
Study: 32075674

Group type: COMPARATOR
Intervention: Combined interscalene brachial plexus with superficial cervical plexus block (IC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined thoracic paravertebral block with brachial plexus and superficial cervical plexus block (ICTP)
Number of subjects: 80
Study: 35761317

Group type: EXPERIMENTAL
Intervention: More intensive intervention arm
Number of subjects: 34

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 34
Study: 34507019

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) program for 8 weeks
Number of subjects: 63
Study: 33940595

Group type: EXPERIMENTAL
Intervention: High threat × Loss frame article
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: High threat × Gain frame article
Number of subjects: 1350
Study: 33267966

Group type: EXPERIMENTAL
Intervention: Positive attitudes
Number of subjects: 5213

Group type: EXPERIMENTAL
Intervention: Negative attitudes
Number of subjects: 5213

Group type: COMPARATOR
Intervention: Abstainers/low users (ABS)
Number of subjects: 5213
Study: 34056987

Group type: EXPERIMENTAL
Intervention: Information‐Motivation and Behavioral skills (IMB) model‐based counseling for four sessions (n = 70)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Antenatal usual care (AUC) (n = 67)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Information‐Motivation and Behavioral skills (IMB) model‐based counseling
Number of subjects: 137
Study: 33920623

Group type: EXPERIMENTAL
Intervention: Strained tomato purée
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rustic tomato purée
Number of subjects: 0
Study: 33028277

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Holding back urine
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Anxiety or irritability
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Contraception
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 272
Study: 36048797

Group type: EXPERIMENTAL
Intervention: Walking impairment (measured by Walking Impairment Questionnaire)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: Walking impairment
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 1696
Study: 34928477

Group type: EXPERIMENTAL
Intervention: rhBMP-2/β-TCP (n = 41, test group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: β-TCP (n = 43, control group)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 34987288

Group type: EXPERIMENTAL
Intervention: CSM-PLT
Number of subjects: 402

Group type: COMPARATOR
Intervention: Conventional ESD
Number of subjects: 402
Study: 33164915

Group type: EXPERIMENTAL
Intervention: Normal night of sleep
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (30 h)
Number of subjects: 16
Study: 616576545

Group type: EXPERIMENTAL
Intervention: Insulin + sitagliptin (100 mg once daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 50
Study: 35556087

Group type: EXPERIMENTAL
Intervention: Clinical vignettes and problem-based learning (PBL) combined with prosected cadavers
Number of subjects: 137
Study: 32102679

Group type: EXPERIMENTAL
Intervention: Basic treatment combined with moving cupping therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Basic treatment combined with moving cupping placebo
Number of subjects: 122
Study: 36190113

Group type: EXPERIMENTAL
Intervention: LIPA
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: EX
Number of subjects: 28
Study: 35446735

Group type: EXPERIMENTAL
Intervention: 7-day mobile-based educational intervention
Number of subjects: 509

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 509
Study: 33752447

Group type: EXPERIMENTAL
Intervention: Novel Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 200
Study: 32925978

Group type: EXPERIMENTAL
Intervention: Urban locations
Number of subjects: 1283

Group type: COMPARATOR
Intervention: Rural locations
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Susceptible individuals in urban areas
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Urban participants with prior history of dengue
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Rural participants who traveled outside their vereda
Number of subjects: 1283

Group type: EXPERIMENTAL
Intervention: Rural participants born outside of Santander department
Number of subjects: 1283
Study: 35565077

Group type: EXPERIMENTAL
Intervention: Mechanical debridement therapy assisted using Bioptron Hyperlight Therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mechanical debridement therapy alone
Number of subjects: 40
Study: 34971065

Group type: EXPERIMENTAL
Intervention: Semi-structured conversations (video chats) with interviewers four times per week for up to one year.
Number of subjects: 39
Study: 35906929

Group type: EXPERIMENTAL
Intervention: Featback, a fully automated online self‐help intervention
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Chat or email support from a recovered expert patient
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Featback with expert‐patient support
Number of subjects: 355

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 355
Study: 32595055

Group type: EXPERIMENTAL
Intervention: IV Lidocaine (5 cc = 100 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: IV Morphine sulfate (5 cc = 5 mg)
Number of subjects: 104
Study: 36380383

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Pharmacy refill count
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Real Time Medication Monitoring (RTMM)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Combination of self-report and pharmacy refill count
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Combination of all three measures (self-report, pharmacy refill count, RTMM)
Number of subjects: 233
Study: 32243365

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over the contralesional premotor area with robotic arm rehabilitation, 10 sessions, 25 minutes each.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS during robotic arm rehabilitation, 10 sessions, 25 minutes each.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Anodal tDCS with robotic arm rehabilitation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS with robotic arm rehabilitation
Number of subjects: 36
Study: 35655850

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group (DG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 80
Study: 32567217

Group type: EXPERIMENTAL
Intervention: Treatment A (3 mg/mL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Treatment B (1 mg/mL)
Number of subjects: 24
Study: 36184889

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33337391

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.75 mg/kg/day for 6 days)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Dexamethasone discontinued after 6 days
Number of subjects: 1